Xarelto (rivaroxaban tablet) is indicated for the prevention of stroke and systemic embolism in patients with AF, in whom anticoagulation is appropriate.
Bayer Corporate Affairs head Doug Grant said, "As a company with a significant and long-standing focus on anticoagulation, we are pleased to see CADTH’s recommendation that provinces reimburse a once-daily treatment that does not require routine blood tests or dose adjustments for AF patients at risk of stroke."
The recommendation is based on evaluation of cost-effectiveness and clinical evidence in the Phase III ROCKET AF study that compared once-daily Xarelto with warfarin.